ZA202311594B - A plurality of tasquinimod particles and use thereof - Google Patents
A plurality of tasquinimod particles and use thereofInfo
- Publication number
- ZA202311594B ZA202311594B ZA2023/11594A ZA202311594A ZA202311594B ZA 202311594 B ZA202311594 B ZA 202311594B ZA 2023/11594 A ZA2023/11594 A ZA 2023/11594A ZA 202311594 A ZA202311594 A ZA 202311594A ZA 202311594 B ZA202311594 B ZA 202311594B
- Authority
- ZA
- South Africa
- Prior art keywords
- tasquinimod
- particles
- tasquinimod particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Powder Metallurgy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21175623 | 2021-05-25 | ||
| PCT/EP2022/063887 WO2022248401A1 (en) | 2021-05-25 | 2022-05-23 | A plurality of tasquinimod particles and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202311594B true ZA202311594B (en) | 2025-04-30 |
Family
ID=76098832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/11594A ZA202311594B (en) | 2021-05-25 | 2023-12-18 | A plurality of tasquinimod particles and use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12485095B2 (enExample) |
| EP (1) | EP4346773B1 (enExample) |
| JP (1) | JP7874664B2 (enExample) |
| KR (1) | KR20240012436A (enExample) |
| CN (1) | CN117295492A (enExample) |
| AU (1) | AU2022281056A1 (enExample) |
| BR (1) | BR112023023715A2 (enExample) |
| CA (1) | CA3218977A1 (enExample) |
| ES (1) | ES3048983T3 (enExample) |
| IL (1) | IL308542A (enExample) |
| MX (1) | MX2023013301A (enExample) |
| PL (1) | PL4346773T3 (enExample) |
| WO (1) | WO2022248401A1 (enExample) |
| ZA (1) | ZA202311594B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025228998A1 (en) * | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| CN104016951B (zh) * | 2010-03-19 | 2016-07-13 | 北京强新生物科技有限公司 | 靶向癌症干细胞的化合物和组合物 |
| WO2012004338A1 (en) | 2010-07-09 | 2012-01-12 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
| WO2015160696A1 (en) | 2014-04-14 | 2015-10-22 | Yale University | Compositions and methods of inhibiting histone deacetylases |
| EP3041472B1 (en) | 2014-09-23 | 2017-02-01 | Active Biotech AB | Quinoline carboxamides for use in the treatment of multiple myeloma |
| BR112017009854B1 (pt) * | 2014-11-19 | 2022-08-23 | Active Biotech Ab | Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| WO2018105943A1 (ko) | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
| WO2018208993A1 (en) * | 2017-05-09 | 2018-11-15 | Dignity Health | Drug delivery composition and method of fabrication |
| US20230293512A1 (en) | 2020-07-23 | 2023-09-21 | Erasmus University Medical Center Rotterdam | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| WO2022152902A1 (en) | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
-
2022
- 2022-05-23 KR KR1020237042849A patent/KR20240012436A/ko active Pending
- 2022-05-23 WO PCT/EP2022/063887 patent/WO2022248401A1/en not_active Ceased
- 2022-05-23 PL PL22730773.3T patent/PL4346773T3/pl unknown
- 2022-05-23 US US18/289,738 patent/US12485095B2/en active Active
- 2022-05-23 AU AU2022281056A patent/AU2022281056A1/en active Pending
- 2022-05-23 ES ES22730773T patent/ES3048983T3/es active Active
- 2022-05-23 CN CN202280034543.8A patent/CN117295492A/zh active Pending
- 2022-05-23 JP JP2023570225A patent/JP7874664B2/ja active Active
- 2022-05-23 EP EP22730773.3A patent/EP4346773B1/en active Active
- 2022-05-23 CA CA3218977A patent/CA3218977A1/en active Pending
- 2022-05-23 BR BR112023023715A patent/BR112023023715A2/pt unknown
- 2022-05-23 MX MX2023013301A patent/MX2023013301A/es unknown
- 2022-05-23 IL IL308542A patent/IL308542A/en unknown
-
2023
- 2023-12-18 ZA ZA2023/11594A patent/ZA202311594B/en unknown
-
2025
- 2025-11-24 US US19/399,224 patent/US20260076908A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4346773B1 (en) | 2025-07-02 |
| US20260076908A1 (en) | 2026-03-19 |
| ES3048983T3 (en) | 2025-12-12 |
| JP7874664B2 (ja) | 2026-06-16 |
| US20240285532A1 (en) | 2024-08-29 |
| KR20240012436A (ko) | 2024-01-29 |
| JP2024520307A (ja) | 2024-05-24 |
| BR112023023715A2 (pt) | 2024-02-20 |
| PL4346773T3 (pl) | 2025-11-03 |
| MX2023013301A (es) | 2023-12-04 |
| AU2022281056A1 (en) | 2023-11-30 |
| IL308542A (en) | 2024-01-01 |
| EP4346773C0 (en) | 2025-07-02 |
| US12485095B2 (en) | 2025-12-02 |
| EP4346773A1 (en) | 2024-04-10 |
| CN117295492A (zh) | 2023-12-26 |
| WO2022248401A1 (en) | 2022-12-01 |
| CA3218977A1 (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3799459C0 (en) | METHOD OF USER EQUIPMENT AND USER EQUIPMENT | |
| ZA202400656B (en) | 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof | |
| SG10202001815VA (en) | Elongated ceiling grid member and ceiling grid assembly including a plurality of the elongated ceiling grid member | |
| GB201910189D0 (en) | A method of making graphene structures and devices | |
| ZA202200168B (en) | New species of stenotrophomonas and application thereof | |
| LT3997032T (lt) | Karbonatinės medžiagos apdorojimas ir gryninimas | |
| GB202002010D0 (en) | Microtopographies and uses thereof | |
| GB2580687B (en) | A packing case and method of manufacture thereof | |
| GB2586580B (en) | LED array and method of forming a LED array | |
| PL3999010T3 (pl) | Artykuł chłonny zawierający rdzeń z naprzemiennymi obszarami materiału chłonnego o wysokiej i niskiej gęstości | |
| IL310096A (en) | CD38 modulators and methods of using them | |
| PL4346773T3 (pl) | Duża liczba cząstek taskwinimodu i ich zastosowanie | |
| IL305789A (en) | USP30 inhibitors and uses thereof | |
| EP4186908C0 (en) | JAK INHIBITOR COMPOUND AND ITS USE | |
| PL3847011T3 (pl) | Laminowana tuba i jej wdrożenia | |
| GB202414054D0 (en) | Bioactives and their uses | |
| GB2604284B (en) | Systems and methods of a climbing wall | |
| IL307897A (en) | AMAROUCIAXANTHIN A COMPOUNDS AND THEIR USES | |
| IL313573A (en) | Transgenic sirpα variants and methods of using them | |
| ZA202104866B (en) | Grinding disc and use of such a grinding disc | |
| GB2609814B (en) | Terpenophenolic compounds and their use | |
| GB202104122D0 (en) | Compounds and their use | |
| GB201811337D0 (en) | Methods of design and manufacture of a component | |
| SI3802637T1 (sl) | Kopolimer in mletje mineralnega materiala | |
| EP4326427A4 (en) | REACTOR ARRANGEMENT AND ITS USE |